CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)
Clinical trials for CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) explained in plain language.
Never miss a new study
Get alerted when new CUTANEOUS LUPUS ERYTHEMATOSUS (CLE) trials appear
Sign up with your email to follow new studies for CUTANEOUS LUPUS ERYTHEMATOSUS (CLE), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug S-4321 tested for multiple autoimmune conditions
Disease control Not yet recruitingThis early-phase study tests an experimental drug called S-4321 in 24 adults with autoimmune diseases like rheumatoid arthritis, psoriasis, lupus, or eczema. The main goal is to check safety and how the body processes the drug. Researchers will also look at early signs of effecti…
Matched conditions: CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)
Phase: PHASE1 • Sponsor: Seismic Therapeutic AU Pty Ltd • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New pill aims to calm lupus skin flares
Disease control Not yet recruitingThis study tests an experimental oral drug, ICP-488, for people with cutaneous lupus erythematosus (CLE), a condition that causes painful skin rashes and lesions. About 105 adults aged 18 to 75 with active skin lupus will receive either the drug or a placebo for 16 weeks. The mai…
Matched conditions: CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)
Phase: PHASE2 • Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. • Aim: Disease control
Last updated May 12, 2026 13:45 UTC
-
New lupus injection enters human testing
Disease control Not yet recruitingThis study tests a new drug called HC022 in 32 people with lupus (SLE or CLE). The main goal is to see if it is safe and tolerable when given as multiple injections under the skin. Researchers will also measure how the drug moves through the body and whether it triggers an immune…
Matched conditions: CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)
Phase: PHASE1 • Sponsor: HC Biopharma Inc. • Aim: Disease control
Last updated May 11, 2026 20:51 UTC